Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company developing therapeutics for rare liver and respiratory diseases and vaccines for infectious diseases. Its internal therapeutic pipeline includes ARCT-810, an mRNA treatment candidate for ornithine transcarbamylase deficiency, and… From the company’s description.
Over the twelve months to Sep 30, 2026, Arcturus Therapeutics Holdings Inc. reported revenue of $30.51M, down 68.7% from a year earlier, and a net loss of $87.24M. Its operating margin was −311.2%, and operations used $62.48M in cash. In fiscal 2025, it reported revenue of $82.03M, down 46.1% from fiscal 2024, and a net loss of $65.78M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Arcturus Therapeutics Holdings Inc. does
In the company’s own words
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company developing therapeutics for rare liver and respiratory diseases and vaccines for infectious diseases. Its internal therapeutic pipeline includes ARCT-810, an mRNA treatment candidate for ornithine transcarbamylase deficiency, and inhaled ARCT-032 for cystic fibrosis; both are in Phase 2 clinical studies. The company’s STARR self-amplifying mRNA platform and LUNAR lipid-mediated delivery system support its medicines development. Arcturus developed KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine approved in Japan, the European Union and the United Kingdom, and commercialized in Japan by Meiji Seika Pharma. Under its collaboration with CSL Seqirus, Arcturus licenses technology and works on vaccines for COVID-19, influenza and other infectious diseases, while CSL Seqirus holds global exclusive rights to develop, manufacture and commercialize those vaccines. The company also conducts early-stage research and manufacturing process development. KOSTAIVE sales began in Japan in October 2024, marking the first commercial sales of an Arcturus-developed product.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1768224
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Arcturus Therapeutics Holdings Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Arcturus Therapeutics Holdings Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Arcturus Therapeutics Holdings Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Arcturus Therapeutics Holdings Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Arcturus Therapeutics Holdings Inc.'s last four quarterly filings that the numbers alone won't show?”